- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03554655
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
The Momentum Trial: The Efficacy of Using a Smartphone Application to Support Shared Decision Making Through Patient Activation in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings
Study Overview
Status
Intervention / Treatment
Detailed Description
Background:
Shared decision making (SDM) may be associated with positive health outcomes for the patient. While practitioners provide a professional expertise with information on the diagnosis, course of the illness, treatment options and potential side effects, patients are experts on their own needs, treatment preferences and goals. In mental healthcare, SDM have been assessed as a promising treatment intervention to promote patient involvement and clinical guidelines advocate the use of SDM as a patient-centered mental health care and a mean to increase patient empowerment. Although SDM today seems to be a preferred model for clinical decision-making for both patients and providers in mental health, patients indicate that they are not involved as much as they want to be in their treatment. Studies on SDM interventions for people with mental health issues are somewhat sparse and due to a small number of RCT studies, the evidence on SDM in mental health has been concluded as encouraging but inconclusive.
Based on recent research, a digital healthcare solution which links patients and providers together could assist in providing support and potentially promote SDM. Findings from existing randomized controlled trials suggest that electronic aids to support SDM are a promising mean to engage patients in their mental health treatment. Recent systematic reviews do, however, highlight a need for more evidence-based research on the efficacy and effectiveness of mental health apps.
Intervention:
Momentum is a smartphone app, developed to support people with schizophrenia-spectrum disorders to prepare for treatment consultations while becoming more involved in treatment decisions. The app was developed in the period of 2013-2014 to support SDM in the Mental Health Services of the Capital Region of Denmark in a process of co-creation. Afterwards, the app was tested by 116 mental health professionals and 78 patients from three different mental health treatment sites: community of mental health, inpatient- and outpatient treatment sites. The app has since then been optimized based on the feedback received from the study participants.
Aim:
The purpose of this trial is to investigate the effects of the smartphone app Momentum for people with a diagnosis of schizophrenia, schizotypal or delusional disorders within outpatient treatment settings in a randomized design. Our main hypothesis is that patients using the Momentum app in combination with receiving specialized early intervention treatment (i.e. treatment as usual (TAU)), compared to patients only receiving TAU, will show greater improvements in patient activation, 6 months after baseline (primary outcome). Our secondary hypothesis is that patients using the Momentum app in combination with receiving TAU, compared to patients only receiving TAU, will show greater improvements regarding self-perceived level of SDM; self-efficacy; the therapeutic alliance; hope and optimism; satisfaction with treatment; patient's confidence in communicating preferences and concerns to their provider; severity of symptoms and; level of functioning (secondary outcomes). Lastly, the investigators hypothesize that there is a correlation between the effects of using the Momentum app and self-reported usefulness of the Momentum app and/or app usage (user sessions per day, screen views per day, screens per session, session duration and session instances, user retention) (explorative outcomes).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amager, Denmark, 2300
- OPUS Amager
-
Ballerup, Denmark, 2750
- OPUS Ballerup
-
Brøndby, Denmark, 2605
- OPUS Glostrup
-
Brøndby, Denmark, 2605
- OPUS Hvidovre
-
Brøndby, Denmark, 2605
- OPUS Valby
-
Hillerød, Denmark, 3400
- OPUS Hillerød
-
København Ø, Denmark, 2100
- OPUS Østerbro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults of both sexes aged 18+
- A diagnosis of schizophrenia, schizotypal or delusional disorder (ICD-10 codes: F20-F29)
- The patient have received treatment for a maximum of 18 months at the start of the intervention from one of five participating OPUS centre in the Mental Health Services of the Capital Region of Denmark
Exclusion Criteria:
- Do not understand or speak Danish
- Unable to give written informed consent to participate in the trial at the described terms
- Are participating in other research studies involving OPUS treatment and an app
- Do not have daily access to a smartphone
- Are suffering of mental retardation or dementia (F. 70-F.79, F.00-F.03)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention: Momentum app
Intervention Group will receive treatment as usual together with the Momentum app.
|
The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider).
Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see.
While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision.
Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
|
No Intervention: Control
Control Group will receive treatment as usual without the Momentum app.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient activation measured with the Consumer Health Activation Index - Mental Health (CHAI-MH)
Time Frame: baseline, 3 months and end of intervention (6 months)
|
Completed by patients.
The 10-item instrument was developed based on 5 key domains: knowledge, self-efficacy, motivation and beliefs, actions, and internal locus of control.
The questionnaire is rated on a 6-point Likert scale ranging from "Strongly disagree" to "Strongly agree".
Afterwards, the scores are transformed into a theoretical value from 0 to 100, with higher scores signifying a stronger involvement in the treatment and confidence in the ability to take care of one's own health and health treatment.
|
baseline, 3 months and end of intervention (6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-efficacy measured with the General Self-Efficacy scale (GSE)
Time Frame: baseline, 3 months and end of intervention (6 months)
|
Completed by patients.
The questions consists of 10 items rated on a 4-point Likert scale ranging from "not at all true" (1) to "exactly true" (4) with higher scores indicating higher self-efficacy.
|
baseline, 3 months and end of intervention (6 months)
|
Change in preparedness for decision making measured with the scale Preparation for Decision Making (PrepDM)
Time Frame: baseline and 6 months
|
Completed by patients.
The 10-item instrument measures the patient's perception of how useful a decision aid or other decision support intervention is.
The questionnaire is rated on a 5-point Likert scale from "Not at all" (1) to "A great deal" (5) with higher scores indicating a higher level of preparedness to communicate with one's care provider regarding health decisions.
|
baseline and 6 months
|
Change in hope measured with the Adult State Hope Scale (ASH)
Time Frame: baseline, 3 months and end of intervention (6 months)
|
Completed by patients.
The 6-item instrument is rated on a Likert-scale from 1-8, with higher scores indicating higher levels of hope.
|
baseline, 3 months and end of intervention (6 months)
|
Change in the efficacy of interactions measured with the scale Perceived Efficacy in Patient-Provider Interactions (PEPPI)
Time Frame: baseline, 3 months and end of intervention (6 months)
|
Completed by patients.
The 5-item instrument measures the assessment of patient's confidence in communicating with their physician.
The questionnaire is rated on a 10-point Likert scale, with higher scores indicating higher perceived efficacy in the interactions
|
baseline, 3 months and end of intervention (6 months)
|
Change in treatment satisfaction measured with the Client Satisfaction Questionnaire (CSQ)
Time Frame: baseline and 6 months
|
Completed by patients.
The 8-item instrument measures a patient's satisfaction with treatment.
Each item is scored on a 4-point Likert scale, with higher scores indicating higher satisfaction.
|
baseline and 6 months
|
App Rating Questionnaire (ARQ) and usage of the Momentum app will be combined to report patients self-perceived usefulness of the app
Time Frame: 6 months
|
Completed by patients in the intervention Group.
ARQ is used to measure the users experience with the app.
Higher scores indicating higher perceived usefulness of the app.
|
6 months
|
Change in treatment alliance measured with the Working Alliance Inventory - short version (WAI-S). Patient version.
Time Frame: baseline and 6 months
|
Completed by patients.
The questionnaire consists of 12 items rated on a 7-point Likert scale, with higher scores indicating better self-perceived working alliance with ones provider.
|
baseline and 6 months
|
Change in treatment alliance measured with the Working Alliance Inventory - short version (WAI-S). Clinician version.
Time Frame: baseline and 6 months
|
Completed by providers.The questionnaire consists of 12 items rated on a 7-point Likert scale, with higher scores indicating better self-perceived working alliance with ones patient.
|
baseline and 6 months
|
Clinical Decision Making Style - Service user (CDMS-P)
Time Frame: baseline
|
Completed by patients.
The 21-item measures preferences in clinical decision making.
The questionnaire is rated on a 5-point Likert scale with higher scores indicating a higher desire to be an active participant in decision making and to be provided with information.
|
baseline
|
Clinical Decision Making Style - Staff questionnaire (CDMS-S).
Time Frame: baseline
|
Completed by providers.
The questionnaire is rated on a 5-point Likert scale with higher scores indicating a higher desire by the clinician for active service user participation in decision making and to provide information to the service user.
|
baseline
|
Service Engagement Scale - Collaboration sub-domain only (SES)
Time Frame: baseline and 6 months
|
Completed by providers.
The scale is a 14-item measurement for the provider to rate their patient's engagement level on the subscale Collaboration.
Each item is scored on a 4 point Likert scale, with higher scores indicating poorer engagement.
|
baseline and 6 months
|
Change in positive symptoms measured by the Scale for the Assessment of Positive Symptoms (SAPS)
Time Frame: baseline and 6 months
|
Each dimension within SAPS is scored between 0-5 with higher scores indicating higher symptom severity
|
baseline and 6 months
|
Change in negative symptoms measured by the Scale for the Assessment of Negative Symptoms (SANS)
Time Frame: baseline and 6 months
|
Each dimension within SANS is scored between 0-5 with higher scores indicating higher symptom severity
|
baseline and 6 months
|
Change in level of functioning measured with the Global Assessment of Functioning (GAF)
Time Frame: baseline and 6 months
|
GAF assesses a person's psychosocial functioning (scores 1-100), with higher scores indicating a higher functioning level.
|
baseline and 6 months
|
Change in level of functioning measured with the Personal and Social Performance Scale (PSP)
Time Frame: baseline and 6 months
|
PSP assesses a person's functioning level within four domains; socially useful activities; Personal and social relationships; Self-care; Disturbing and aggressive behaviors.
PSP is scored 1-100, with higher scores indicating a higher functioning level.
|
baseline and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective data on app usage
Time Frame: 3 months and 6 months
|
Objective data covers: user sessions per day, screen views per day, screens per session, session duration and session instances, user retention
|
3 months and 6 months
|
Anti-psychotic medicine
Time Frame: baseline and 6 months
|
Use and adherence of anti-psychotic medicine
|
baseline and 6 months
|
Adherence to treatment
Time Frame: baseline, 3 months and 6 months
|
number of no-shows to treatment consultations compared to number of planned consultations
|
baseline, 3 months and 6 months
|
Hospital admissions
Time Frame: baseline, 3 months and 6 months
|
Number of hospital admissions
|
baseline, 3 months and 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lisa Korsbek, ph.d., Mental Health Services in the Region of Southern Denmark, Odense
Publications and helpful links
General Publications
- Vitger T, Hjorthoj C, Austin SF, Petersen L, Tonder ES, Nordentoft M, Korsbek L. A Smartphone App to Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled Assessor-Blinded Trial. J Med Internet Res. 2022 Oct 26;24(10):e40292. doi: 10.2196/40292.
- Vitger T, Austin SF, Petersen L, Tonder ES, Nordentoft M, Korsbek L. The Momentum trial: the efficacy of using a smartphone application to promote patient activation and support shared decision making in people with a diagnosis of schizophrenia in outpatient treatment settings: a randomized controlled single-blind trial. BMC Psychiatry. 2019 Jun 17;19(1):185. doi: 10.1186/s12888-019-2143-2.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 115441
- H-17025550 (Other Identifier: Regional Ethics Committee in The Capital Region of Denmark)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia, Schizotypal and Delusional Disorders
-
Mental Health Services in the Capital Region, DenmarkOdense University Hospital; Copenhagen Trial Unit, Center for Clinical Intervention... and other collaboratorsCompletedRecurrent Depressive Disorder | Bipolar Affective Disorder | Schizophrenia, Schizotypal and Delusional DisordersDenmark
-
Mental Health Services in the Capital Region, DenmarkCentral Denmark Region; Mental Health Services in the North Denmark RegionActive, not recruitingPsychotic Disorders | Schizophrenia and Related Disorders | Schizotypal Disorder | Schizophrenia Prodromal | Paranoid Schizophrenia | Paranoid Ideation | Paranoid Delusion | Ideas of Reference | Psychosis Paranoid | Psychotic Paranoia | Psychotic; Disorder, DelusionalDenmark
-
Jeremy KoppelNational Institute of Mental Health (NIMH)RecruitingLate Onset Schizophrenia | Delusional Disorder (Late Onset)United States
-
German Research FoundationUnknownSchizophrenia | Delusional Disorders (ICD-10)Germany
-
Research Foundation for Mental Hygiene, Inc.National Institute of Mental Health (NIMH); University of Maryland; Maryland... and other collaboratorsCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychosis | Delusional DisorderUnited States
-
University of CologneUniversity Hospital Tuebingen; University Hospital FrankfurtUnknownPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Delusional DisorderGermany
-
Mental Health Services in the Capital Region, DenmarkRecruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Depression Severe | Schizotypal Disorder | Acute and Transient Psychotic Disorder, Unspecified | Non-Organic Psychosis | Substance Induced PsychosesDenmark
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Delusional Disorder | Psychotic DisorderCanada
-
Queen Margaret UniversityNHS LothianUnknownSupported Accommodation Residents | Schizophrenia, Shizotypal and Delusional Disorders | Mood Affective Disorders | Disorders of Adult Personality and BehaviorUnited Kingdom
-
National Taiwan University HospitalCompletedSchizophrenia | Latent Schizophrenia
Clinical Trials on Momentum app
-
University of NebraskaNational Institute of Nursing Research (NINR)Completed
-
University of VictoriaRecruiting
-
Hypnalgesics, LLCTufts UniversityCompletedDental Anxiety | Opioid Use | Drug Use | Dental PainUnited States
-
Barbara Ann Karmanos Cancer InstituteCompletedCancer | Financial Toxicity | Question Prompt ListUnited States
-
Chang Gung UniversityChang Gung Memorial HospitalRecruiting
-
University of California, San FranciscoConquer Cancer FoundationActive, not recruitingProstate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
The University of Hong KongNot yet recruitingDigital Health | Knee Pain/OsteoarthritisHong Kong
-
University of Sao PauloNot yet recruitingPostpartum Depression
-
Florida Atlantic UniversityActive, not recruitingHealth BehaviorUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed